Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate
/in Hypernephroma, International Publications /von 2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-9Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81Vaccination strategies in patients with renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses
/in Hypernephroma, International Publications /von 2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-97Vaccine therapy in patients with renal cell carcinoma
/in Hypernephroma, International Publications, IOZK Veröffentlichungen /von 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
/in Hypernephroma, International Publications /von 2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-41Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
/in Hypernephroma, International Publications /von 2008-10-01 / J. Immunother. 2008 Oct;31(8):771-80Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-8Delivery of whole tumor lysate into dendritic cells for cancer vaccination
/in Dendritic Cells, Hypernephroma, International Publications, NSCLC /von 2008-01-01 / Methods Mol. Biol. 2008;423:139-53
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma